OncoCyte (NASDAQ:OCX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCXFree Report) in a report released on Thursday morning. The brokerage issued a sell rating on the stock.

Other research analysts also recently issued reports about the stock. Needham & Company LLC reissued a buy rating and set a $4.25 price objective on shares of OncoCyte in a research report on Thursday, May 16th. Benchmark reaffirmed a speculative buy rating and issued a $5.00 target price on shares of OncoCyte in a research report on Monday, April 15th. Finally, Stephens reaffirmed an equal weight rating and issued a $4.00 target price on shares of OncoCyte in a research report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, OncoCyte has a consensus rating of Hold and an average price target of $4.06.

Read Our Latest Research Report on OCX

OncoCyte Price Performance

Shares of OncoCyte stock opened at $2.74 on Thursday. The company’s fifty day simple moving average is $2.77 and its two-hundred day simple moving average is $3.05. OncoCyte has a 12-month low of $2.08 and a 12-month high of $4.86.

Insider Transactions at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of OncoCyte stock in a transaction dated Thursday, April 11th. The shares were purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the transaction, the insider now directly owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Andrew Arno purchased 33,898 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were bought at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the purchase, the director now directly owns 69,054 shares in the company, valued at approximately $203,709.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the purchase, the insider now owns 4,929,066 shares in the company, valued at $14,392,872.72. The disclosure for this purchase can be found here. Insiders have acquired 2,457,288 shares of company stock valued at $7,176,400 in the last three months. 1.94% of the stock is currently owned by company insiders.

OncoCyte Company Profile

(Get Free Report)

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.

Read More

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.